Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Stuart A. Arbuckle sold 4,250 shares of the business’s stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $159.00, for a total value of $675,750.00. Following the completion of the sale, the executive vice president now owns 46,202 shares in the company, valued at approximately $7,346,118. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded down $0.47 on Friday, reaching $157.93. The company had a trading volume of 1,561,110 shares, compared to its average volume of 1,550,901. Vertex Pharmaceuticals Incorporated has a twelve month low of $79.78 and a twelve month high of $167.85. The company has a current ratio of 3.28, a quick ratio of 3.14 and a debt-to-equity ratio of 0.01. The company has a market cap of $39,940.00, a PE ratio of 202.47, a PEG ratio of 1.84 and a beta of 1.58.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.49. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The business had revenue of $578.20 million for the quarter, compared to analysts’ expectations of $522.07 million. During the same quarter in the prior year, the business earned $0.16 EPS. The firm’s revenue for the quarter was up 39.7% on a year-over-year basis. analysts predict that Vertex Pharmaceuticals Incorporated will post 0.76 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of VRTX. Northwestern Mutual Wealth Management Co. raised its stake in Vertex Pharmaceuticals by 15.4% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock valued at $127,000 after acquiring an additional 132 shares during the period. Smithfield Trust Co. bought a new stake in Vertex Pharmaceuticals in the 3rd quarter valued at $135,000. FNY Managed Accounts LLC acquired a new position in Vertex Pharmaceuticals in the 3rd quarter valued at $162,000. Fuller & Thaler Asset Management Inc. acquired a new position in Vertex Pharmaceuticals in the 3rd quarter valued at $198,000. Finally, Commerce Bank acquired a new position in Vertex Pharmaceuticals in the 2nd quarter valued at $206,000. Institutional investors and hedge funds own 93.09% of the company’s stock.

A number of equities research analysts have recently issued reports on VRTX shares. Royal Bank of Canada started coverage on Vertex Pharmaceuticals in a research note on Thursday, September 14th. They set an “outperform” rating and a $175.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and set a $195.00 price objective on shares of Vertex Pharmaceuticals in a research note on Sunday, September 17th. Vetr cut Vertex Pharmaceuticals to a “sell” rating in a research note on Thursday, September 21st. Zacks Investment Research upgraded Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $174.00 price objective on the stock in a research note on Tuesday, September 26th. Finally, BMO Capital Markets reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, September 27th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, twenty-five have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $175.89.

COPYRIGHT VIOLATION WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) EVP Stuart A. Arbuckle Sells 4,250 Shares” was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2018/01/12/vertex-pharmaceuticals-incorporated-vrtx-evp-stuart-a-arbuckle-sells-4250-shares.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.